Functional activity of CD34-positive cells in chronic myeloid leukemia patients with different response to imatinib therapy by Sviezhentseva, I.O. et al.
70 Experimental Oncology 37, 70–72, 2015 (March)
FUNCTIONAL ACTIVITY OF CD34-POSITIVE CELLS IN CHRONIC 
MYELOID LEUKEMIA PATIENTS WITH DIFFERENT RESPONSE 
TO IMATINIB THERAPY
I.O. Sviezhentseva1, T.P. Perekhrestenko2, D.I. Bilko1, A.I. Gordienko2, M.V. Diachenko1, I.S. Dyagil3
1Centre for Molecular and Cell Research of National University of “Kyiv-Mohyla Academy”, Kyiv 04655, Ukraine
2SI “Institute of Hematology and Transfusiology of the NAMS of Ukraine”, Kyiv 04060, Ukraine
3SI “The National Research Center for Radiation Medicine of the NAMS of Ukraine”, Kyiv 04050, Ukraine
Introduction: It is believed that the reason of the leukemic clone cell resistance to treatment with tyrosine kinase inhibitors during 
chronic myeloid leukemia (CML) is mutations in the genome of an early bone marrow progenitor cells that are CD34-positive. Such 
cells, regardless of treatment, acquire ability to proliferation and differentiation. This leads to the re-expansion of the CD34+ cells. 
Aim: to determine the CD34 antigen expression in bone marrow and peripheral blood cells in CML patients with different response 
to imatinib therapy using the results of hematopoietic cells culturing and the data of flow cytometry. Methods: Bone marrow aspirate 
from 39 patients who were treated with imatinib was studied with cytogenetic, flow cytometry and culture methods in vitro. Results: In pa-
tients with an optimal response to imatinib therapy the number of colonies was 1.8 times lower than the number of those in the group 
of patients with a suboptimal response to therapy. In turn, in patients with failure of imatinib therapy the number of colonies was 
the highest and was 2.1 times higher than the patients with optimal response. The results of cytometric studies have shown that 
the number of CD34+ cells in bone marrow was significantly higher compared to the number of CD34+ cells in peripheral blood cells 
and increased with the acquisition of leukemic cells the resistance to imatinib. There was a direct correlation between the number 
of colonies and clusters in semisolid agar in vitro and the number of CD34+ cells in the bone marrow of patients. Conclusions: The cor-
relation between the number of CD34+ cells and the number of cell aggregates in semisolid agar in vitro indicates the prognostic value 
of the method for determining CD34+ cells in the patient bone marrow. The parallel increase of their number in the peripheral blood 
will allow developing express methods for the detection of individual patient response to imatinib therapy.
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Chronic myeloid leukemia (CML) is a myeloproliferative 
neoplasm that characterized the expansion of the early he-
matopoietic progenitor cells pool which express CD34 an-
tigen [1, 2]. It is known that the diffe rentiation of bone 
marrow cells expression of CD34 antigen on the cell 
surface of myeloid hematopoiesis decreases or disap-
pears [3]. In general, the function of CD34 antigen is still 
not clear, but it is believed that it plays an important role 
in the interaction between hematopoietic cells and bone 
marrow microenvironment [4, 5].
The cause of CML is tyrosine kinase activity of BCR-
ABL oncoprotein, which is expressed by derivative 
chromosome 22. It is called the Philadelphia chromo-
some (Ph-chromosome) [6]. Due to the aforemen-
tioned activity of this oncoprotein the leukemic clone 
cell is not only characterized by altered potential for 
self-renewal and differentiation, but also by the re-
duced the levels of adhesion to bone marrow stroma. 
As a result a large number of early CD34-positive 
hematopoietic cells get to the peripheral blood [7, 8].
The BCR-ABL tyrosine kinase is a therapeutic target 
of the imatinib which is the first-generation of tyrosine 
kinase inhibitors (TKI) [9]. Early clinical studies have 
revealed that 65–85% of patients had a complete cyto-
genetic remission received after 12 months of imatinib 
therapy which was much more effective compared 
to other therapeutic agents, known at that time.  However, 
a part of the patients (approximately 30%) did not achieve 
a complete cytogenetic response within 1 year of treat-
ment [10]. Some researchers consider that the resis-
tance is caused by mutations in the genome of bone 
marrow progenitor cells that are CD34-positive. Such 
cells, regardless of treatment, get on ability to active 
proliferation and differentiation. This leads to the re-
expansion of the pool of CD34+ cells [3]. That is why 
immunophenotypic monitoring of CD34+ cells in periphe-
ral blood and bone marrow should be conducted for 
the prognosis of the disease and evaluation of the ef-
fectiveness of therapy in CML patients [11, 12].
The aim of this work was to determine the features 
of CD34 antigen expression in bone marrow and pe-
ripheral blood in CML patients with different response 
to imatinib therapy using the results of hematopoietic 
cells culturing and the data of flow cytometry.
MATERIALS AND METHODS
We studied the bone marrow samples of 39 CML 
patients during the chronic phase of disease treated with 
imatinib for at least 12 months. The average age of patients 
was 54.0 ± 7.41 years. All patients before the study signed 
a voluntary informed consent. All patient samples were ob-
tained under Research Ethics Board. According to the cri-
teria for assessing the effectiveness of tyrosine kinases 
therapy of The European LeukemiaNet the patients were 
divided into three groups: with optimal (n = 15), subopti-
mal response (n = 10) and failure (n = 14) of the imatinib 
therapy. The optimal response means a complete cyto-
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genetic response after 12 months of therapy with imatinib 
(0% Ph-positive cells). Suboptimal response was defined 
when the bone marrow research showed from 1% to 35% 
of Ph-positive cells after 12 months of imatinib therapy. 
The lack of response to the drug indicated the presence 
of a large number of cells with Ph-chromosome, which 
is greater than 35% in the bone marrow [13].
To determine the functional activity of hematopoietic 
cells of patients in vitro culturing of bone marrow mono-
nuclear cells in semisolid agar (“Difco”, USA) (concen-
tration 0.33%) with a use of the medium for culturing 
RPMI-1640 (“Sigma”, USA), 20% fetal calf serum and 
antibiotics (50 IU/ml penicillin, 50 mg/ml streptomycin) 
was carried out. Cultivation was performed for 13 days 
under conditions of absolute humidity, 5% CO2 and 
at 37 °C. A cluster-forming units included no more than 
40 cells, at the same time the colony consists of from 
40 to several hundred cells (Fig. 1). A proliferative 
potential was determined as the ratio of the number 
of colonies and the number of clusters.
a
b
Fig. 1. Colony (a) and cluster (b) formed by culturing bone mar-
row cells of patients with CML in vitro
To assess the phenotypic characteristics of he-
matopoietic cells of patients the method of direct flow 
cytometry was used. For this purpose, bone mar-
row mononuclear cells were stained with mono-
clonal antibodies (“Becton Dickinson”, USA) using 
the method provided by the manufacturer. Flow 
cytometry study was performed using a flow cytome-
ter laser FACScan (“Becton Dickinson”, USA) with 
an argon laser which has a wavelength of 488 nm. 
Data collection was performed by flow cytometry using 
the  LYSYS-II Ver. 1.1 (“Becton Dickinson”, USA) soft-
ware. The program WinMDI 2.8 (Joseph Trotter, Scripps 
Institute, La Jolla, CA) was used to analyze the results.
The statistical analysis of the results was carried 
out using nonparametric Mann — Whi tney tests for 
comparing two populations. The conclusion of the sta-
tistical significance of the results made at p < 0.05. For 
estimation of interrelations between obtained indexes 
the correlational analysis with determination of Pear-
son’s correlation coefficient has been conducted.
RESULTS AND DISCUSSION
In general, the determination of the number of colo-
nies in semisolid agar in vitro is used as a test system 
to check the impact of chemotherapeutic agents 
on the leukemic clone cells [14]. However, such stu dies 
are usually implemented under conditions of the pre-
sence of chemotherapeutic agents in the culture medi-
um. Culture of bone marrow subjected to therapy with 
TKI and with the absence of imatinib in the cultivation 
medium may allow reproducing the features of bone 
marrow cells proliferation without the inhibitory effect 
of the drug. The previous studies have demonstrated 
that the determination of functional activity of bone 
marrow cells of CML patients in semisolid agar in vitro 
with different response to imatinib therapy may have 
prognostic value for assessing the further develop-
ment of the disease [15, 16]. However, a problem 
of finding the predictive test systems that would be ef-
ficient and quick remains open. Therefore, it appeared 
reasonable to compare the results of cultivation with 
the number of cells expressing CD34 antigen.
The results of cultivation suggest that in patients with 
an optimal response to imatinib therapy the number 
of colonies was 1.8 times lower than the number of those 
in the group of patients with suboptimal response 
to thera py (Table 1). In turn, in patients with fa ilure of ima-
tinib therapy the number of colonies was the highest 
and was 2.1 times higher than the patients with optimal 
response. In the case of clusters was recorded tendency 
to increase this indicator in patients with suboptimal 
response and treatment failure. In addition, the patients 
with inefficiency and suboptimal response to imatinib 
therapy had the significantly higher proliferative potential 
than in patients with optimal response. This may indicate 
that early progenitor cells dominated the more diffe-
rentiated cells which form clusters in the culture. In turn, 
in the bone marrow of patients who have increasing 
numbers of leukemic clone cells proliferation processes 
dominate over the processes of differentiation that may 
be the cause of the increase of the number of colonies 
in semisolid agar in vitro [17].
Table 1. Characteristics of the functional activity of bone marrow cells 
in patients with different response to imatinib therapy
The response 
to imatinib therapy
The number 
of colonies
The number 
of clusters
Proliferative 
potential
Optimal response 34.42 ± 1.46 46.01 ± 2.27 0.94 ± 0.04
Suboptimal response 63.75 ± 2.57* 54.25 ± 4.68 1.19 ± 0.02*
Failure of the therapy 73.81 ± 3.2* 54.53 ± 3.7 1.41 ± 0.05*
*Statistically significant differences with group of optimal response (p < 0.05).
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The results of cytometry analysis showed that 
in patients with the acquisition of resistance to imatinib 
the number of CD34+ cells increases in the bone mar-
row and peripheral blood (Table 2). It should be noted, 
in patients with different response to therapy the num-
ber of CD34 antigen in bone marrow and peripheral 
blood was significantly different. This may indicate that 
during the progression of CML and during the acquisi-
tion of resistance to the drug by leukemic clone cells 
the pool of early progenitor cells not only expands, 
but also, due to the weakening of contacts between 
the cells of the microenvironment and leukemic clone 
cells, the early progenitor cells fall in blood flow in large 
numbers, promoting a poorly differentiated hemato-
poietic cells in peripheral blood of patients [5].
Table 2. Expression of CD34 antigen on hematopoietic progenitor cells 
in the bone marrow and peripheral blood of CML patients with different 
response to imatinib therapy (% ± m%)
The response 
to imatinib therapy
The number of CD34+ 
bone marrow cells
The number of CD34+ 
peripheral blood cells
Optimal response 9.23 ± 2.01 4.43 ±1.07
Suboptimal response 31.65 ± 5.85* 12.08 ± 5.35*
Failure of the therapy 44.37 ± 6.72* 17.95 ± 4.42*
*Statistically significant differences with group of optimal response (p < 0.05).
A correlation analysis was conducted to identify 
the correspondence between the number of CD34+ cells 
in the bone marrow and in peripheral blood of patients tre-
ated with imatinib. These results indicate a direct correlation 
between the number of colonies and clusters in semisolid 
agar in vitro and the number of CD34+ cells in the patient 
bone marrow (r = 0.83 and r = 0.58, p < 0.05) (Fig. 2).
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Fig. 2. Correlation between number of CD34+ cells in the pa-
tients bone marrow, the number of colonies (a) and the number 
of clusters (b)
Thus, the number of CD34+ cells in the bone marrow 
of patients increases with the acquisition of leukemic 
clone cells resistance to imatinib. The correlation between 
the number of CD34+ cells and the number of cell aggre-
gates in semisolid agar in vitro, which may be predictive 
method for determining the future course of CML, shows 
the prognostic value of method for determining the CD34+ 
cells in the bone marrow of patients; and a parallel increase 
of their number in the peripheral blood of patients will allow 
to develop express methods for the detection of individual 
patient response to imatinib therapy.
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